Results 61 to 70 of about 1,454 (181)

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source

Mode and site of action of therapies targeting CGRP signaling

The Journal of Headache and Pain, 2023
Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system.
Alejandro Labastida-Ramírez, Edoardo Caronna, Cédric Gollion, Emily Stanyer, Austeja Dapkute, Diana Braniste, Hoda Naghshineh, Liga Meksa, Nino Chkhitunidze, Tamari Gudadze, Patricia Pozo-Rosich, Rami Burstein, Jan Hoffmann   +12 more
doaj   +1 more source

Advances in pharmaceutic managements of migraine

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
Migraine is a neurovascular disorder with great burden so that effective abortive and preventive treatment is needed. Different from the previous choice of drugs based on clinical experience, the specific treatment targeting the pathogenesis of migraine ...
LI Yan⁃sheng
doaj   +1 more source

Anti-migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice [PDF]

, 2020
Objective: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRPmediated vasodilation is, however, a critical rescue mechanism in ischemia.
van den Bogaerdt, A., Maassen van den Brink, A. (Antoinette), MaassenVanDenBrink, A., Maagdenberg, A.M.J.M. (Arn), de Vries, T., Sugimoto, K., Qin, T., Ferrari, M.D., Danser, A.H.J. (Jan), Li, M. (Minghui), Bogaerdt, A. van den, Mulder, I.A., Wermer, M.J.H. (Marieke), Vries, T. de, Yanagisawa, T., Danser, A.H.J., Maagdenberg, A.M.J.M. van den, Ferrari, M.D. (Michel), Ayata, C., Li, M., Wermer, M.J.H.   +20 more
core   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

Brain Sciences
Objectives: The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks.
Emmanouil V. Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S. Vlachos, Georgios G. Vasiliadis, Andreas A. Argyriou   +9 more
doaj   +1 more source

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

The Journal of Headache and Pain, 2023
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the ...
Marta Waliszewska-Prosół, Doga Vuralli, Paolo Martelletti   +2 more
doaj   +1 more source

Serum Concentration Relationships of Candesartan in Migraine Prevention

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Migraine is a common disabling disorder, and optimising affordable preventive treatments remains highly relevant. Candesartan is an effective and well‐tolerated preventive treatment, but little is known about its dose‐concentration–response relationships.
Hedda Skogum Riise, Melanie Simpson, Ketil Arne Espnes, Erling Andreas Tronvik, Andreas Kattem Husøy, Lise R. Øie, Anker Stubberud, Emil Kofoed, Aurora Harsvik Alstad, Hedda Hoff Hagen, Maren Guldteig Lien, Marie Larsen Stavseng, Ella Rian Sæther, Tore Wergeland   +13 more
wiley   +1 more source

Update on gepants for the treatment of chronic migraine

Journal of the Chinese Medical Association
Chronic migraine (CM) is a profoundly debilitating condition that has detrimental clinical and social outcomes. Over the past two decades, novel small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, known as gepants, and CGRP monoclonal antibodies (mAbs) have been developed, ushering in a new era of migraine-specific treatment. In
Aoh, Yu, Hou, Tsung-Wei, Yang, Cheng-Chia, Chang, Ching-Mao, Chen, Shih-Pin, Tsai, I-Ju, Cheng, Chin-Wen, Yang, Chun-Pai   +7 more
openaire   +2 more sources

Neues in der Migränetherapie:Calcitonin gene-related peptide (CGRP) und sein Rezeptor als Ansatzpunkt

, 2021
Migräne patients need effective acute medication and the more severe cases need preventive treatment. Recently, drugs that directly interact with migraine pathophysiology by blocking the CGRP pathway have been developed. On one hand, there are antibodies
Ruscheweyh, Ruth, Hoffmann, Jan; id_orcid, Jan Hoffmann, Ruth Ruscheweyh   +3 more
core   +1 more source